Mga Batayang Estadistika
| LEI | 529900NF00G2BB523B88 |
| CIK | 1444192 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Grace Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 27, 2025 |
Exhibit 99.1 Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported by Positive Results from Phase 3 STRIVE-ON Safe |
|
| August 12, 2025 |
Exhibit 99.1 Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) NDA Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provi |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) ( |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace Ther |
|
| July 28, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 25, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 25, 2025 |
Exhibit 99.1 Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trigger Exercise of up to $7. |
|
| June 23, 2025 |
Grace Therapeutics, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 Grace Therapeutics, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Grace Therapeutics, Inc. (the “Company”) on November 10, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best inte |
|
| June 23, 2025 |
Employment Agreement by and between Carrie D’Andrea and the Company, dated July 1, 2023 Exhibit 10.11 June 21, 2023 PRIVATE AND CONFIDENTIAL DELIVERED BY EMAIL Carrie D’Andrea Dear Carrie: We are pleased to extend the following offer of employment with Acasti Pharma Inc. (“Acasti”): Title: Vice President, Clinical Operations Reporting to: Prashant Kohli, Chief Executive Officer Base Salary: Annualized base salary of $275,000, less applicable deductions and withholdings. Annual Bonus: |
|
| June 23, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Grace Therapeutics, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), is our com |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Co |
|
| June 23, 2025 |
Grace Therapeutics, Inc. Insider Trading Policy Exhibit 19.1 GRACE THERAPEUTICS, INC. INSIDER TRADING POLICY Last updated: June 21, 2025 INTRODUCTION U.S. federal and state laws prohibit buying, selling, gifting, or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such Material Nonpublic Information (as defined herein) from |
|
| June 23, 2025 |
Exhibit 21.1 Grace Therapeutics, Inc. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Percent Owned Grace Therapeutics U.S., Inc. (formerly Acasti Pharma U.S., Inc.) Delaware, United States 100% |
|
| June 23, 2025 |
Employment Agreement by and between Amresh Kumar and the Company, dated May 8, 2023 Exhibit 10.10 May 3, 2023 (revised on May 11, 2023) PRIVATE AND CONFIDENTIAL DELIVERED BY EMAIL Amresh Kumar Dear Amresh: We are pleased to extend the following offer of employment with Acasti Pharma Inc. (“Acasti”): Title: Vice President, Program Management Reporting to: Prashant Kohli, Chief Executive Officer Base Salary: Annualized base salary of $275,000, less applicable deductions and withhol |
|
| June 23, 2025 |
Form of Indemnification Agreement between Grace Therapeutics, Inc. and its directors and officers Exhibit 10.12 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, the Board of Directors o |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace Therapeutic |
|
| June 23, 2025 |
Employment Agreement by and between R. Loch Macdonald and the Company, dated May 7, 2024 Exhibit 10.18 May 7, 2024 PRIVATE AND CONFIDENTIAL DELIVERED BY EMAIL R. Loch Macdonald Dear Loch: We are pleased to extend the following offer of employment with Acasti Pharma Inc. (“Acasti”): Title: Chief Medical Officer (CMO) Reporting to: Prashant Kohli, Chief Executive Officer Base Salary: Annualized base salary of $200,000, less applicable deductions and withholdings. Annual Bonus: You will |
|
| June 23, 2025 |
Exhibit 99.1 Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial |
|
| April 9, 2025 |
Exhibit 99.1 Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104 NDA Submission Anticipated Q2 Calendar 2025 Princeton, NJ, April 9, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being |
|
| April 9, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 12, 2025 |
GRACE THERAPEUTICS, INC. 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 GRACE THERAPEUTICS, INC. 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 March 12, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Grace Therapeutics, Inc. Registration Statement on Form S-3 Filed March 10, 2025 File No. 333-285661 Request for Acceleration |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 10, 2025 Registration Statement No. |
|
| March 10, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Grace Therapeutics, Inc. |
|
| March 3, 2025 |
Exhibit 99.1 Corporate Presentation March 2025 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| February 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace |
|
| February 13, 2025 |
Exhibit 10.1 GRACE THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN 1. PURPOSE The Plan is intended to (a) provide eligible persons with an incentive to contribute to the success of the Company and to operate and manage the Company’s business in a manner that will provide for the Company’s long-term growth and profitability to benefit its stockholders and other important stakeholders, including its e |
|
| February 13, 2025 |
Exhibit 10.3 Grant No. GRACE Therapeutics, INC. 2024 EQUITY INCENTIVE PLAN Nonqualified STOCK OPTION AGREEMENT COVER SHEET Grace Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), to the Grantee named below, subject to the vesting and other conditions set forth |
|
| February 13, 2025 |
Exhibit 10.2 Grant No. GRACE Therapeutics, INC. 2024 EQUITY INCENTIVE PLAN Incentive STOCK OPTION AGREEMENT COVER SHEET Grace Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), to the Grantee named below, subject to the vesting and other conditions set forth bel |
|
| February 13, 2025 |
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update Exhibit 99.1 Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025 Secured Private Placement Financing of $15 Million in Upfront Gross Procee |
|
| February 10, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 10, 2025, by and among Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliveri |
|
| February 10, 2025 |
Exhibit 99.1 Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 Princeton, NJ, February 10, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE), |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 10, 2025 |
Exhibit 99.3 Grace Therapeutics Announces Private Placement Financing of up to $30 Million Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an additional $15 million in potential warrant exercise proceeds for an aggregate of up to ap |
|
| February 10, 2025 |
Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH S |
|
| February 10, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 10, 2025, by and among Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliveri |
|
| February 10, 2025 |
Exhibit 99.2 Corporate Presentation February 2025 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Excha |
|
| February 10, 2025 |
Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN |
|
| February 10, 2025 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 10, 2025, is entered into by and among Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms |
|
| November 14, 2024 |
LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation" ), does hereby make, constitute, and appoint each of Marie Andre, Andres Ortiz Custodio, Kamil Dziedzic, Valerie Ezeagbo, Kelvin Kwo k, Frank Lui, James Todd, Ben Tsoi, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting for th |
|
| November 14, 2024 |
ACST / Grace Therapeutics, Inc. / ADAR1 Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Grace Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00430K865 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 14, 2024 |
ACST / Grace Therapeutics, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G/A 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* GRACE THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00439U104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) |
|
| November 13, 2024 |
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update Exhibit 99.1 Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update STRIVE-ON Data Readout Expected First Calendar Quarter 2025; NDA Submission on Track for 1H Calendar 2025 Completed Corporate Re-Branding, Connecting Company to Rich Scientific Legacy of Grace Therapeutics Announced Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Tr |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 28, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ACASTI PHARMA INC. Acasti Pharma Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: That the first Article of the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”) is hereby amended and restated in it |
|
| October 28, 2024 |
Exhibit 3.2 BYLAWS OF GRACE THERAPEUTICS, INC. ARTICLE I. OFFICES Section 1.01 Registered Office. The registered office and registered agent of Grace Therapeutics, Inc. (the “Corporation”) in the State of Delaware shall be as set forth in the Corporation’s certificate of incorporation as then in effect (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation |
|
| October 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| October 25, 2024 |
Exhibit 99.1 Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20th Princeton, NJ, October 25, 2024 (GL |
|
| October 8, 2024 |
As filed with the Securities and Exchange Commission on October 8, 2024 As filed with the Securities and Exchange Commission on October 8, 2024 Registration No. |
|
| October 8, 2024 |
As filed with the Securities and Exchange Commission on October 8, 2024 As filed with the Securities and Exchange Commission on October 8, 2024 Registration Statement No. |
|
| October 8, 2024 |
As filed with the Securities and Exchange Commission on October 8, 2024 As filed with the Securities and Exchange Commission on October 8, 2024 Registration No. |
|
| October 8, 2024 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Acasti Pharma Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.0001 per share Other 1,350,000 $ 2.91 $ 3,928,500.00 0.0001531 $ 601.45 Total Offering |
|
| October 8, 2024 |
As filed with the Securities and Exchange Commission on October 8, 2024 As filed with the Securities and Exchange Commission on October 8, 2024 Registration No. |
|
| October 8, 2024 |
As filed with the Securities and Exchange Commission on October 8, 2024 As filed with the Securities and Exchange Commission on October 8, 2024 Registration No. |
|
| October 8, 2024 |
As filed with the Securities and Exchange Commission on October 8, 2024 As filed with the Securities and Exchange Commission on October 8, 2024 Registration No. |
|
| October 7, 2024 |
CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Exhibit 3.1 Mailing Address: Location: PO Box 9431 Stn Prov Govt 2nd Floor - 940 Blanshard Street Victoria BC V8W 9V3 Victoria BC www.corporateonline.gov.bc.ca 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT T.K. SPARKS This Notice of Articles was issued by the Registrar on: October 1, 2024 |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 7, 2024 |
EXHIBIT 3.3 CERTIFICATE OF INCORPORATION OF ACASTI PHARMA INC. I, the undersigned, for the purposes of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware, do execute this Certificate of Incorporation and do hereby certify as follows: ARTICLE I The name of the corporation (the “Corporation”) is Acasti Pharma Inc. ARTICLE II The address of the regis |
|
| October 7, 2024 |
Exhibit 4.1 THIS CERTIFIES THAT is the owner of DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Acasti Pharma Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This |
|
| October 7, 2024 |
EXHIBIT 3.4 BYLAWS OF ACASTI PHARMA INC. ARTICLE I. OFFICES Section 1.01 Registered Office. The registered office and registered agent of Acasti Pharma Inc. (the “Corporation”) in the State of Delaware shall be as set forth in the Corporation’s certificate of incorporation as then in effect (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). Section |
|
| October 7, 2024 |
ARTICLES ACASTI PHARMA INC. (the “Company”) EXHIBIT 3.2 Incorporation number: C1504591 ARTICLES of ACASTI PHARMA INC. (the “Company”) TABLE OF CONTENTS 1. INTERPRETATION 1 1.1 Definitions 1 1.2 Business Corporations Act and Interpretation Act Definitions Applicable 2 2. SHARES AND SHARE CERTIFICATES 2 2.1 Authorized Share Structure 2 2.2 Form of Share Certificate 2 2.3 Shareholder Entitled to Certificate or Acknowledgement 2 2.4 Delivery by |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in its Charter) Québec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 30, 2024 |
ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN EXHIBIT 10.1 ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN 1. PURPOSE The Plan is intended to (a) provide eligible persons with an incentive to contribute to the success of the Company and to operate and manage the Company’s business in a manner that will provide for the Company’s long-term growth and profitability to benefit its stockholders and other important stakeholders, including its employe |
|
| September 25, 2024 |
Exhibit 99.1 Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025 Princeton, NJ, September 25, 2024 (GLOBE NEWSWIRE)- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation o |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☐ Definitive Proxy Statem |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 16, 2024 |
Letter Agreement by and between Prashant Kohli and the Company, dated August 12, 2024. Exhibit 10.1 August 12, 2024 PRIVATE AND CONFIDENTIAL Prashant Kohli 31 Northrup Court, Newtown, PA 18940 [email protected] Dear Prashant: This Letter Agreement (“Letter Agreement”) sets forth the terms and conditions of your employment with Acasti Pharma Inc. (the "Company”), and supersedes in its entirety the Welcome Letter between you and Acasti, dated August 25, 2021. Title: Chief Executive O |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 9, 2024 |
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update Exhibit 99.1 Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update • Surpassed 50% Enrollment Milestone in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 • Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA Submission on Track for 1H Calendar 2025 • Projected Cash Runway into Second Calendar Quarter 2 |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti Pha |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☐ Definitive Proxy Statem |
|
| August 7, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-280536 Proxy Statement and Management Information Circular of Acasti Pharma Inc. with respect to its Annual and Special Meeting of Shareholders and Prospectus of Acasti Pharma Inc. AUTHORIZING THE CONTINUANCE, AUTHORIZING THE DOMESTICATION, APPROVAL OF 2024 EQUITY INCENTIVE PLAN, ELECTION OF DIRECTORS, INDEPENDENT REGISTERED |
|
| July 31, 2024 |
July 31, 2024 CORRESPONDENCE FILED VIA EDGAR Office of Life Sciences Division of Corporation Finance U. |
|
| July 31, 2024 |
As filed with the Securities and Exchange Commission on July 31, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. |
|
| July 31, 2024 |
Exhibit 99.1 |
|
| July 10, 2024 |
EX-99.A 2 tm2419166d1ex99-a.htm EXHIBIT A EXHBIIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of common stock, no par value, of Acasti Pharma Inc. dated as of July 10, 2024 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions |
|
| July 10, 2024 |
ACST / Acasti Pharma Inc. / ADAR1 Capital Management, LLC - SC 13G Passive Investment SC 13G 1 tm2419166d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ACASTI PHARMA INC. (Name of Issuer) Class A Common Stock, no par value (Title of Class of Securities) 00430K865 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| June 27, 2024 |
As filed with the Securities and Exchange Commission on June 27, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 27, 2024 Registration No. |
|
| June 27, 2024 |
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial Exhibit 99.1 Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with Potential NDA Submission on Track for 1H Calendar 2025 Princeton, NJ, June 27, 2024 (GLOBE NEWSWIRE)- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma comp |
|
| June 27, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 27, 2024 |
ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN Nonqualified STOCK OPTION AGREEMENT COVER SHEET Exhibit 10.4 Grant No. ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN Nonqualified STOCK OPTION AGREEMENT COVER SHEET Acasti Pharma Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), to the Grantee named below, subject to the vesting and other conditions set forth below (the “ |
|
| June 27, 2024 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Acasti Pharma Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, the Board of Directors of the C |
|
| June 27, 2024 |
ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN Incentive STOCK OPTION AGREEMENT COVER SHEET Exhibit 10.3 Grant No. ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN Incentive STOCK OPTION AGREEMENT COVER SHEET Acasti Pharma Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), to the Grantee named below, subject to the vesting and other conditions set forth below (the “Cov |
|
| June 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Acasti Pharma Inc. |
|
| June 27, 2024 |
Exhibit 99.1 |
|
| June 21, 2024 |
Acasti Announces Year-End 2024 Financial Results, Provides Business Update Exhibit 99.1 Acasti Announces Year-End 2024 Financial Results, Provides Business Update • Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025 • Projected Cash Runway into Second Calendar Quarter 2026 Princeton, NJ, June 21, 2024 (GLOBE NEWSWIRE)- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, b |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 ACASTI PHARMA INC |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 21, 2024 |
Exhibit 21.1 Acasti Pharma Inc. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Percent Owned Acasti Pharma U.S., Inc. New Jersey, United States 100% |
|
| June 21, 2024 |
Acasti Pharma Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 Acasti Pharma Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) on November 10, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the |
|
| April 9, 2024 |
ACST / Acasti Pharma Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Acasti Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00430K865 (CUSIP Number) March 27, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ☐ Rule 1 |
|
| April 1, 2024 |
Company Overview NASDAQ: ACST April 2024 Company Overview NASDAQ: ACST April 2024 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U. |
|
| April 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 13, 2024 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Szabina Biro, Hannah Chae, Andres Ortiz Custodio, Kamil Dziedzic, Krishnan Harihanran, Kelvin Kwok, Frank Lui, James Todd, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting |
|
| February 13, 2024 |
CA00430K8656 / ACASTI PHARMA INC / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Acasti Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00430K865 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti |
|
| February 12, 2024 |
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights • Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA) • Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track for NDA Submission Timeline • Poster Highlighting the STRIVE-ON Trial Presented |
|
| February 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 8, 2024 |
November 20, 2023 PRIVATE AND CONFIDENTIAL DELIVERED BY EMAIL Robert DelAversano Dear Robert: We are pleased to extend the following offer of employment with Acasti Pharma Inc. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 15, 2023 |
Letter from Ernst & Young LLP (Canada), dated December 15, 2023. Ernst & Young s.r.l./S.E.N.C.R.L. Ernst & Young LLP 900, boul. De Maisonneuve Ouest Bureau 2300 Montréal (Québec) H3A 0A8 Tél./Tel : +1 514 875 6060 Téléc./Fax : +1 514 879 2600 ey.com December 15, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated December 15, 2023, of Acasti Pharma Inc. and are in agreement with |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 13, 2023 |
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 Acasti Announces Second Quarter 2024 Financial Results and Business Highlights • Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 • Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well Beyond Anticipated Submission of GTX-104 New Drug Application (NDA) • Highlighted the Potential of GTX-1 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acast |
|
| October 23, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 23, 2023 |
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial Exhibit 99.1 Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial • With achievement of enrollment milestone, pivotal STRIVE-ON safety trial on track for potential NDA submission anticipated to occur in the first half of calendar 2025 • Recently announced $7.5 million private placement financing extends projected cash runway to the first calendar quarter of 2026 PRINCETON, N.J., Oct |
|
| October 23, 2023 |
Exhibit 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (the “Settlement Agreement”) is entered into as of October 18, 2023 by and between (1) Acasti Pharma Inc., a corporation organized and existing under the laws of Québec, Canada, with its principal place of business located at 2572 boul. Daniel-Johnson, 2nd Floor, Laval, Québec, Canada H7T 2R3 (“Acasti”), and (2) Aker BioMarine Antarctic A |
|
| October 16, 2023 |
PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-274899 6,594,615 Common Shares The selling shareholders (the “Selling Shareholders”) named in this prospectus may use this prospectus to offer and resell from time to time up to 6,594,615 of our common shares, no par value per share, which are comprised of (i) 1,951,371 common shares (the “Shares”), (ii) 2,106,853 common shares (the |
|
| October 12, 2023 |
ACASTI PHARMA INC. 2572 boul. Daniel-Johnson. 2nd Floor Laval, Québec, Canada H7T 2R3 ACASTI PHARMA INC. 2572 boul. Daniel-Johnson. 2nd Floor Laval, Québec, Canada H7T 2R3 October 12, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Acasti Pharma Inc. Registration Statement on Form S-3 Filed October 6, 2023 File No. 333-274899 Request for Acceleration of E |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Acasti Pharma Inc. |
|
| October 6, 2023 |
UNOFFICIAL TRANSLATION PREPARED BY OSLER Exhibit 4.1 CERTIFICATE OF AMENDMENT Business Corporations Act (CQLR, chapter S-31.1) I attest that the legal person ACASTI PHARMA INC. has modified its articles pursuant to the Business Corporations Act (Québec) to integrate the changes outlined in the attached articles. July 10, 2023 at 12:01 a.m. Filed in the register on July 4, 2023 under the Québec Reg |
|
| October 6, 2023 |
As filed with the Securities and Exchange Commission on October 6, 2023 As filed with the Securities and Exchange Commission on October 6, 2023 Registration Statement No. |
|
| September 26, 2023 |
EX-4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION |
|
| September 26, 2023 |
Acasti Announces $7.5 Million Private Placement Equity Financing EX-99.1 Acasti Announces $7.5 Million Private Placement Equity Financing Princeton, NJ, September 26, 2023 (GLOBE NEWSWIRE)- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that i |
|
| September 26, 2023 |
EX-4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION |
|
| September 26, 2023 |
EX-10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 24, 2023, between Acasti Pharma Inc., a corporation incorporated under the Business Corporations Act (Québec) (formerly Part 1A of the Companies Act (Québec)) and domiciled in Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its su |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 25, 2023 |
As filed with the Securities and Exchange Commission on August 25, 2023 As filed with the Securities and Exchange Commission on August 25, 2023 Registration No. |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 25, 2023 |
Exhibit 107 Calculation of Filing Fees Table Form S-8 (Form Type) Acasti Pharma Inc. |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti Pha |
|
| August 11, 2023 |
Acasti Announces First Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 Acasti Announces First Quarter 2024 Financial Results and Business Highlights • New leadership team singularly focused on executing GTX-104 strategy • Announced alignment with the U.S. Food and Drug Administration (FDA) for Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 with first patient expected to be dosed prior to the end of 2023 • Cash and cash equivalents as of quarter end w |
|
| August 11, 2023 |
Form of Stock Option Agreement for Employees under the Acasti Pharma Inc. Stock Option Plan Exhibit 10.1 ACASTI PHARMA INC. STOCK OPTION PLAN AS AMENDED SEPTEMBER 28, 2022 OPTION AGREEMENT (the “Option Agreement”) Acasti Pharma Inc. (the “Company”) hereby grants the following Options to you subject to the terms and conditions of this Option Agreement, together with the provisions of the Company’s Stock Option Plan as amended September 28, 2022 (the “Plan”), all the terms of which Plan ar |
|
| August 11, 2023 |
Exhibit 10.2 ACASTI PHARMA INC. STOCK OPTION PLAN AS AMENDED SEPTEMBER 28, 2022 OPTION AGREEMENT (the “Option Agreement”) Acasti Pharma Inc. (the “Company”) hereby grants the following Options to you subject to the terms and conditions of this Option Agreement, together with the provisions of the Company’s Stock Option Plan as amended September 28, 2022 (the “Plan”), all the terms of which Plan ar |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 11, 2023 |
Exhibit 3.4 GENERAL BY-LAW 2020-1 OF ACASTI PHARMA INC. (the “Corporation”) DOCPROPERTY "DocsID" \* MERGEFORMAT LEGAL1:62166140.2 TABLE OF CONTENTS 1 - DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretation 1 1.3 Execution in Counterpart, by Facsimile and by Electronic Signature 1 2 - GENERAL BUSINESS 2 2.1 Head Office 2 2.2 Establishment 2 2.3 Seal 2 2.4 Fiscal Year 2 2.5 Execution of Instruments 2 2 |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 7, 2023 |
EX 3.1 CERTIFICATE OF AMENDMENT Business Corporations Act (CQLR, chapter S-31.1) I attest that the legal person ACASTI PHARMA INC. has modified its articles pursuant to the Business Corporations Act (Québec) to integrate the changes outlined in the attached articles. July 10, 2023 at 12:01 a.m. Filed in the register on July 4, 2023 under the Québec Registration Number 1160589793. (Signed) Registra |
|
| July 7, 2023 |
Acasti Pharma Announces 1-for-6 Reverse Stock Split EX 99.1 Acasti Pharma Announces 1-for-6 Reverse Stock Split LAVAL, Québec, July 7, 2023 - Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will effect a 1-for- |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 04, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 05, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 5, 2023 |
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 STRIVE-ON is the pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH GTX-104 has been administered in over 150 healthy volunteers to-date and has demonstrated comparable safety profile to oral nimodipine Company confirms its projected cash runway through a potential GTX-104 New Drug Application (NDA) submission in the first half of calendar 2025 LAVAL, QC, July 5, 2023 /PRNewswire/ - Acasti Pharma Inc. |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 ACASTI PHARMA INC |
|
| June 23, 2023 |
Acasti Pharma Reports Fiscal Year 2023 Operational Results Acasti Pharma Reports Fiscal Year 2023 Operational Results LAVAL, Québec, June 23, 2023 /PRNewswire/ - Acasti Pharma Inc. |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 5, 2023 |
Acasti Announces Appointment of Prashant Kohli as CEO Acasti Announces Appointment of Prashant Kohli as CEO LAVAL, Québec, April 4, 2023 - Acasti Pharma Inc. |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 04, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 5, 2023 |
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND Company expects the first patient to be enrolled during the second half of 2023 LAVAL, Québec, April 4, 2023 - Acasti Pharma Inc. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 13, 2023 |
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange Acasti also confirms no exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank LAVAL, Québec, March 13, 2023 – Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical stage drug candidates ad |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 23, 2023 |
Letter from KPMG LLP dated February 22, 2023 KPMG LLP Tour KPMG, Suite 1500 600 de Maisonneuve Blvd. West Montréal (Québec) H3A 0A3 Tel. 514-840-2100 Fax 514-840-2187 www.kpmg.ca February 22, 2023 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Acasti Pharma Inc. and, under the date of June 21, 2022, we reported on the consolidated financial statements of Acasti Pha |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti |
|
| February 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 14, 2023 |
Acasti Pharma Reports Third Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, February 14, 2023 - Acasti Pharma Inc. |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 14, 2022 |
Acasti Pharma Reports Second Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET LAVAL, Qu?bec, November 14, 2022 - Acasti Pharma Inc. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acast |
|
| September 30, 2022 |
Acasti Announces Court Dismissal of Stockholder Litigation Acasti Announces Court Dismissal of Stockholder Litigation LAVAL, Qu?bec, Sept. 30, 2022 (GLOBENEWSWIRE) ? Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today that a U.S. court has dismissed the remaining stockholder litigation filed |
|
| September 30, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 29, 2022 |
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders Laval, Qu?bec, CANADA, September 29, 2022 ?Acasti Pharma Inc. |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 11, 2022 |
Acasti Pharma Reports First Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET LAVAL, Qu?bec, August 11, 2022 - Acasti Pharma Inc. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti Pha |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 23, 2022 |
ACASTI PHARMA INC. Up to $11,050,000 Common Shares 424B3 1 atmsupplement.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-239538 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 9, 2021) ACASTI PHARMA INC. Up to $11,050,000 Common Shares This prospectus supplement amends and supplements the information in our prospectus, dated November 21, 2021 (the “Prospectus”), filed pursuant to our registration statement on Form S-3 (File No. |
|
| June 21, 2022 |
Acasti Pharma Reports Fiscal Year 2022 Operational Results Company to Host Conference Call Today at 1:00pm ET For Immediate Release LAVAL, Qu?bec, June 21, 2022 (PR NEWSWIRE) - Acasti Pharma Inc. |
|
| June 21, 2022 |
DESCRIPTION OF ACASTI PHARMA INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary sets forth certain material terms and provisions of Acasti Pharma Inc.?s (the ?Company?, ?Acasti?, ?our?, ?we?) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following description |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 ACASTI PHARMA INC |
|
| June 21, 2022 |
Acasti Pharma Inc., Stock Option Plan, as amended June 24, 2021. ACASTI PHARMA INC. STOCK OPTION PLAN THIS PLAN adopted October 8, 2008, amended on April 29, 2009, March 1, 2011, May 22, 2013, October 5, 2015, May 11, 2016, June 8, 2017, July 27, 2018, April 15, 2019, March 31, 2020, August 27, 2020 and June 24, 2021. ARTICLE 1 DEFINITIONS AND INTERPRETATION 1.1 Definitions. Where used in this Plan, unless there is something in the subject matter or context inc |
|
| June 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 21, 2022 |
Employment Agreement with Brian Ford dated September 23, 2021. EXECUTION VERSION EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made this 1st day of [September] 2021 between ACASTI PHARMA INC. |
|
| May 18, 2022 |
ACASTI PHARMA ANNOUNCES POSITIVE RESULTS FOR PHARMACOKINETIC BRIDGING STUDY, WITH INTRAVENOUS GTX-104 MEETING ALL ENDPOINTS Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104 Phase 3 remains on track to start before year-end A conference call to discuss the results scheduled for Wednesday May 18th at 1:00 PM Eastern Time LAVAL, Qu?bec, May 18, 2022 (GLOBE NEWSWIRE) - Acasti Pharma Inc. |
|
| May 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 25, 2022 |
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors LAVAL, Qu?bec, March 25, 2022 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST) today announces that it has appointed Michael L. Derby to its Board of Directors. ?Michael is a successful pharma industry leader whose extensive involvement in drug repurposing an |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti |
|
| February 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 14, 2022 |
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022 Provides updates on key milestones: GTX-104 PK study remains on track for results to be reported in the first half of calendar 2022; GTX-102 and GTX-101 progressing on schedule Conference call to be held on Monday, February 14th at 1:00 p. |
|
| December 2, 2021 |
EXHIBIT 99.1 Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104 Bioavailability of GTX-104 compares favorably with the oral formulation of nimodipine; full PK study expected to report out as planned in H1?22 LAVAL, Qu?bec, Dec. 02, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST), today announced po |
|
| December 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 15, 2021 |
Acasti Pharma Announces Annual Stock Option Grants EXHIBIT 99.1 Acasti Pharma Announces Annual Stock Option Grants LAVAL, Qu?bec, Nov. 12, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST), today announced the annual grant of stock options to its employees, executives and directors. An aggregate of 2,077,900 options to purchase common shares of the Company were granted under the Company?s stock o |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acast |
|
| November 10, 2021 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022 Conference call to be held on Wednesday, November 10th at 1:00 p.m. ET LAVAL, Québec, Nov. 10, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced its operating and financial re |
|
| November 10, 2021 |
Up to US$75,000,000 Common Shares PROSPECTUS SUPPLEMENT (to Prospectus dated June 29, 2020) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 5, 2021 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 26, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorpora |
|
| November 5, 2021 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Form 8-K/A of Acasti Pharma, Inc. to be filed on or about November 5, 2021 and to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-239538) and on Form S-8 (No. 333-191383 and No. 333-227476) of Acasti Pharma, Inc. of our report dated March 26, 2021, on our aud |
|
| September 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Qu?bec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 22, 2021 |
EXHIBIT 99.1 Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards LAVAL, Qu?bec, Sept. 22, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (?Nasdaq?) has confirmed to Acasti that the Company has |
|
| September 9, 2021 |
Articles of Amendment of Acasti Pharma Inc. (English translation) Exhibit 3.1 CERTIFICATE OF AMENDMENT Business Corporations Act (CQLR, chapter S-31.1) I attest that the legal person ACASTI PHARMA INC. has modified its articles pursuant to the Business Corporations Act (Qu?bec) to integrate the changes outlined in the attached articles. August 27, 2021 Filed in the register on August 26, 2021 under the Qu?bec Registration Number 1160589793. (Signed) Registraire |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 7, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 27, 2021 |
Exhibit 99.2 Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split LAVAL, Qu?bec, Aug. 26, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti?) (NASDAQ: ACST?TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (? |
|
| August 27, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT Business Corporations Act (CQLR, chapter S-31.1) I attest that the legal person ACASTI PHARMA INC. has modified its articles pursuant to the Business Corporations Act (Qu?bec) to integrate the changes outlined in the attached articles. August 27, 2021 Filed in the register on August 26, 2021 under the Qu?bec Registration Number 1160589793. (Signed) Registraire |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 26, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 27, 2021 |
Exhibit 99.1 VIA SEDAR August 27, 2021 Autorit? des march?s financiers Alberta Securities Commission British Columbia Securities Commission Manitoba Securities Commission Ontario Securities Commission Subject: Acasti Pharma Inc. (the ?Corporation?) Report on the Voting Results, in accordance with article 11.3 of Regulation 51-102 respecting Continuous Disclosure Obligations (?Regulation 51-102?) F |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Qu?bec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti Pha |
|
| August 12, 2021 |
EXHIBIT 99.1 Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022 August 4th webcast replay discussing planned acquisition of Grace Therapeutics available on the Company?s website Shareholders urged to vote in advance of upcoming shareholder meeting on August 26th LAVAL, Qu?bec, Aug. 12, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Qu?bec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 12, 2021 |
EXHIBIT 99.1 Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022 August 4th webcast replay discussing planned acquisition of Grace Therapeutics available on the Company?s website Shareholders urged to vote in advance of upcoming shareholder meeting on August 26th LAVAL, Qu?bec, Aug. 12, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and |
|
| August 4, 2021 |
Filed by Acasti Pharma Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Acasti Pharma Inc. Commission File No.: 001-35776 Crescendo Communications, llC To: Acasti and Grace Management From Crescendo Communications Subject: Acasti/Grace Acquisition Call Date: August 4, 2021 I. Introduction ? |
|
| August 4, 2021 |
YOUR VOTE IS IMPORTANT PLEASE VOTE YOUR PROXY TODAY Filed by Acasti Pharma Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Acasti Pharma Inc. Commission File No.: 001-35776 YOUR VOTE IS IMPORTANT PLEASE VOTE YOUR PROXY TODAY August 4, 2021 Dear Stockholder: We are reaching out regarding the proxy materials we recently sent you in connection |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 23, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) QUEBEC, CANADA 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 23, 2021 |
Exhibit 99.1 Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special meeting of shareholders LAVAL, Qu?bec, July 23, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST) announces it |
|
| July 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 23, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) QUEBEC, CANADA 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 23, 2021 |
Exhibit 99.1 Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special meeting of shareholders LAVAL, Qu?bec, July 23, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST) announces it |
|
| July 21, 2021 |
Exhibit 99.1 Case 1:21-cv-06051 Document 1 Filed 07/14/21 Page 1 of 21 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK LAUDEN BISEL, Plaintiff, Case No.: -against- COMPLAINT ACASTI PHARMA, INC., RODERICK DEMAND FOR JURY TRIAL CARTER, JAN D?ALVISE, JOHN CANAN, and DONALD OLDS, Defendants. Plaintiff, Lauden Bisel (?Plaintiff?), by his undersigned attorneys, alleges upon personal knowledge |
|
| July 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 21, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) QUEBEC, CANADA 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 21, 2021 |
Exhibit 99.1 Case 1:21-cv-06051 Document 1 Filed 07/14/21 Page 1 of 21 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK LAUDEN BISEL, Plaintiff, Case No.: -against- COMPLAINT ACASTI PHARMA, INC., RODERICK DEMAND FOR JURY TRIAL CARTER, JAN D?ALVISE, JOHN CANAN, and DONALD OLDS, Defendants. Plaintiff, Lauden Bisel (?Plaintiff?), by his undersigned attorneys, alleges upon personal knowledge |
|
| July 21, 2021 |
Exhibit 99.2 Case 1:21-cv-01039-UNA Document 1 Filed 07/16/21 Page 1 of 10 PageID #: 1 UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE SEAN DAWSON, ) ) Plaintiff, ) ) Case No. v. ) ) JURY TRIAL DEMANDED ACASTI PHARMA, INC., RODERICK ) CARTER, JAN D?ALVISE, JOHN CANAN, ) DONALD OLDS, ACASTI PHARMA U.S., ) INC., and GRACE THERAPEUTICS, INC., ) ) Defendants. ) COMPLAINT FOR VIOLATION OF THE SECURIT |
|
| July 21, 2021 |
Exhibit 99.2 Case 1:21-cv-01039-UNA Document 1 Filed 07/16/21 Page 1 of 10 PageID #: 1 UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE SEAN DAWSON, ) ) Plaintiff, ) ) Case No. v. ) ) JURY TRIAL DEMANDED ACASTI PHARMA, INC., RODERICK ) CARTER, JAN D?ALVISE, JOHN CANAN, ) DONALD OLDS, ACASTI PHARMA U.S., ) INC., and GRACE THERAPEUTICS, INC., ) ) Defendants. ) COMPLAINT FOR VIOLATION OF THE SECURIT |
|
| July 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 21, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) QUEBEC, CANADA 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 15, 2021 |
MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-257589 MERGER PROPOSAL?YOUR VOTE IS VERY IMPORTANT As previously announced on May 7, 2021, Acasti Pharma Inc. (?Acasti?), Acasti Pharma U.S., Inc. (?MergerCo?), a wholly-owned subsidiary of Acasti, and Grace Therapeutics Inc. (?Grace?) entered into an Agreement and Plan of Merger (the ?merger agreement?), pursuant to which Mer |
|
| July 13, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on July 13, 2021 Registration No. |
|
| July 13, 2021 |
Acasti Pharma Inc. 3009 boul. De la Concorde E., Suite 102 Laval, Québec, Canada H7E 2B5 Acasti Pharma Inc. 3009 boul. De la Concorde E., Suite 102 Laval, Qu?bec, Canada H7E 2B5 July 13, 2021 VIA EDGAR Fredrick Philantrope Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Acasti Pharma Inc. Registration Statement on Form S-4 Filed June 30, 2021 (as amended July 13, 2021) File No. 333-257589 Dear Mr. Philantrope: Pursuant t |
|
| July 13, 2021 |
Consent of Oppenheimer & Co. Inc. EX-99.1 5 d136282dex991.htm EX-99.1 Exhibit 99.1 Consent of Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (“Oppenheimer”) hereby consents to the inclusion of our opinion letter, dated May 6, 2021 to the Board of Directors (in its capacity as such) of Acasti Pharma Inc. (“Acasti”) included as Annex B, and to the references thereto under the captions “Summary – Opinion of the Acasti Financial Adviso |
|
| July 1, 2021 |
GRACE THERAPEUTICS INC. AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENTS Exhibit 10.10 GRACE THERAPEUTICS INC. AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENTS THIS AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENTS (this ?Amendment?) is made as of [ , 2018] by and among Grace Therapeutics Inc., a Delaware corporation (the ?Company?), and the undersigned Purchasers. Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in the Origi |
|
| July 1, 2021 |
Consent of Oppenheimer & Co. Inc. Exhibit 99.1 Consent of Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (?Oppenheimer?) hereby consents to the inclusion of our opinion letter, dated May 6, 2021 to the Board of Directors (in its capacity as such) of Acasti Pharma Inc. (?Acasti?) included as Annex B, and to the references thereto under the captions ?Summary ? Opinion of the Acasti Financial Advisor,? ?The Merger ? Background of the |
|
| July 1, 2021 |
GRACE THERAPEUTICS INC. FIRST AMENDMENT TO THE STOCKHOLDERS’ AGREEMENT Exhibit 10.13 GRACE THERAPEUTICS INC. FIRST AMENDMENT TO THE STOCKHOLDERS? AGREEMENT THIS FIRST AMENDMENT TO THE STOCKHOLDERS? AGREEMENT (this ?Amendment?) is made as of May 31, 2018 by and among Grace Therapeutics Inc., a Delaware corporation (the ?Company?), and the undersigned Stockholders. Capitalized terms used but not defined herein have the meaning assigned to such terms in that certain Sto |
|
| July 1, 2021 |
GRACE THERAPEUTICS INC. STOCKHOLDERS’ AGREEMENT Exhibit 10.12 GRACE THERAPEUTICS INC. STOCKHOLDERS? AGREEMENT THIS STOCKHOLDERS? AGREEMENT (this ?Agreement?) is made and entered into as of this 12th day of April, 2018 (the ?Effective Date?) by and among Grace Therapeutics Inc., a Delaware corporation (the ?Company?), those certain stockholders of the Company listed on Schedule A and any subsequent stockholders who become party hereto as ?Pharma |
|
| July 1, 2021 |
Consent to be Named as a Director Nominee Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Acasti Pharma Inc., of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Acasti Pharma Inc. |
|
| July 1, 2021 |
Consent to be Named as a Director Nominee Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Acasti Pharma Inc., of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Acasti Pharma Inc. |
|
| July 1, 2021 |
Exhibit 10.11 GRACE THERAPEUTICS INC. SECOND AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENTS AND AMENDMENT TO CONVERTIBLE PROMISSORY NOTES THIS SECOND AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENTS AND AMENDMENT TO CONVERTIBLE PROMISSORY NOTES (this ?Amendment?) is made as of [ , 2020], by and among Grace Therapeutics Inc., a Delaware corporation (the ?Company?), and the undersigned purchaser |
|
| July 1, 2021 |
AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTE $[ ] [ , 2018] Exhibit 10.6 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE CO |
|
| July 1, 2021 |
GRACE THERAPEUTICS INC. CONVERTIBLE NOTE PURCHASE AGREEMENT EX-10.7 5 d136282dex107.htm EX-10.7 Exhibit 10.7 GRACE THERAPEUTICS INC. CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the “Agreement”) is made as of the day of [ , 2018] by and between Grace Therapeutics Inc., a Delaware corporation (the “Company”) having an office at 2 Tower Center Blvd., Suite 1101, East Brunswick, NJ 08816, and the purchaser identified on the si |
|
| July 1, 2021 |
CONVERTIBLE PROMISSORY NOTE $[ ] [ ], 2017 Exhibit 10.5 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE CO |
|
| July 1, 2021 |
Exhibit 99.2 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com 000001 Mr A Sample Designation (if any) Add1 Add2 add3 add4 add5 add6 Security Class 123 Holder Account Number C1234567890 IND Fold Form of Proxy - Annual General and Special Meeting to be held on XX, 2021 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has th |
|
| July 1, 2021 |
As filed with the Securities and Exchange Commission on June 30, 2021 Table of Contents As filed with the Securities and Exchange Commission on June 30, 2021 Registration No. |
|
| July 1, 2021 |
EX-10.9 7 d136282dex109.htm EX-10.9 Exhibit 10.9 GRACE THERAPEUTICS INC. AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENT AND AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTES THIS AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENT AND AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTES (this “Amendment”) is made as of [ , 2020], by and among Grace Therapeutics Inc., a Delaware corporation (the “Compa |
|
| July 1, 2021 |
GRACE THERAPEUTICS INC. CONVERTIBLE PROMISSORY NOTE [US$ ] [ , 2018] EX-10.4 2 d136282dex104.htm EX-10.4 Exhibit 10.4 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUN |
|
| July 1, 2021 |
GRACE THERAPEUTICS LLC CONVERTIBLE NOTE PURCHASE AGREEMENT EX-10.8 6 d136282dex108.htm EX-10.8 Exhibit 10.8 GRACE THERAPEUTICS LLC CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the “Agreement”) is made as of the day of [, 2017] by and between Grace Therapeutics LLC, a New Jersey limited liability company (the “Company”) and each of the purchasers listed on Exhibit A attached to this Agreement (each a “Purchaser” and togethe |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 ACASTI PHARMA INC |
|
| June 22, 2021 |
Acasti Pharma Inc., Stock Option Plan, as amended August 27, 2020. EX-10.3 3 exh103.htm EXHIBIT 10.3 Exhibit 10.3 ACASTI PHARMA inc. STOCK OPTION PLAN AS AMENDED August 27, 2020 acasti pharma inc. STOCK OPTION PLAN THIS PLAN adopted October 8, 2008, amended on April 29, 2009, March 1, 2011, May 22, 2013, October 5, 2015, May 11, 2016, June 8, 2017, July 27, 2018, April 15, 2019, March 31, 2020 and August 27, 2020. Article 1 DEFINITIONS AND INTERPRETATION 1.1 Defi |
|
| June 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 22, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) QUEBEC, CANADA 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 22, 2021 |
EXHIBIT 99.1 Acasti Pharma Provides Fiscal 2021 Year-End Business Update Update on Acquisition of Grace Therapeutics and Strategic Plans for CaPre LAVAL, Qu?bec, June 22, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST) today announced its operating and financial results for the fiscal year ended March 31, 2021, and provided an update on its pla |
|
| June 22, 2021 |
Acasti Pharma Inc., Equity Incentive Plan, as amended August 27, 2020. Exhibit 10.2 ACASTI PHARMA inc. equity incentive PLAN lAST aMENDED AUGUST 27, 2020 Acasti Pharma Inc. Equity Incentive Plan ARTICLE 1 Purpose 1.1 Purpose The purpose of this Plan is to provide the Corporation with a share-related mechanism to attract, retain and motivate qualified Directors, Employees and Consultants of the Corporation and its Subsidiaries, to reward such of those Directors, Emplo |
|
| June 22, 2021 |
Exhibit 10.6 INDEPENDENT CONTRACTOR AGREEMENT THIS INDEPENDENT CONTRACTOR AGREEMENT (the "Agreement") 1s made September 14, 2020 (the "Effective Date"). BETWEEN: ACASTI PHARMA INC. (the "Company") - and- PFC BUSINESS ADVISORY SERVICES INC. (the "Contractor") (collectively referred to as the "Parties") WHEREAS the Company wishes to retain the Contractor as an independent contractor to provide certa |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 11, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) QUEBEC, CANADA 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 17, 2021 |
Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance EXHIBIT 99.1 Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance LAVAL, Qu?bec, May 17, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST) today announced that, on May 11, 2021, the Company received notice from the Nasdaq Listing Qualifications Department (the ?Staff?) indicating that, based upon the Company?s non-c |
|
| May 7, 2021 |
EX-99.2 5 exh992.htm EXHIBIT 99.2 Exhibit 99.2 1 Non - Confidential Information Presentation May 2021 DW1 Disclaimer This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval . The proposed transaction will be submitted to the shareholders of Acasti Pharma Inc . (“Acasti”) for their consideration . Acasti |
